Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Prostatitis secondary prevention

Introduction

Overview

Overview

Secondary preventive therapies struggle due to developing resistance in the strains causing prostatitis. Fosfomycin given before urogenital procedures is helpful in preventing prostatitis. Ginsenoid has a preventive effect on chronic bacterial prostatitis but some still consider it controversial due to lack of evidence.[1]

Secondary Prevention

Secondary Prevention

The following facts about secondary prevention of prostatitis must be kept in mind[2][3]

  • Due to resistant strains, empiric antibiotics are not as effective in preventing episodes of prostatitis.
  • Fosfomycin has bee used prophylactically in patients undergoing TURP.
  • Ginsenoid is effective in preventing chronic bacterial prostatitis.
References

References

  1. ↑ Sang Hoon Kim, U.-Syn Ha, Dong Wan Sohn, Seung-Ju Lee, Hyun Woo Kim, Chang Hee Han & Yong-Hyun Cho (2012). “Preventive effect of ginsenoid on chronic bacterial prostatitis”. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 18 (5): 709–714. doi:10.1007/s10156-012-0406-7. PMID 22450878. Unknown parameter |month= ignored (help)
  2. ↑ Sang Hoon Kim, U.-Syn Ha, Dong Wan Sohn, Seung-Ju Lee, Hyun Woo Kim, Chang Hee Han & Yong-Hyun Cho (2012). “Preventive effect of ginsenoid on chronic bacterial prostatitis”. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 18 (5): 709–714. doi:10.1007/s10156-012-0406-7. PMID 22450878. Unknown parameter |month= ignored (help)
  3. ↑ B. J. Gardiner, A. A. Mahony, A. G. Ellis, N. Lawrentschuk, D. M. Bolton, P. T. Zeglinski, A. G. Frauman & M. L. Grayson (2014). “Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?”. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 58 (4): e101–e105. doi:10.1093/cid/cit704. PMID 24170195. Unknown parameter |month= ignored (help)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]